3 ms·
Very exciting, we're going to see some serious "at scale" behavioral changes (obesity decline, addiction decline, possibly even social media usage decline) as s
by toomuchtodo 2y ago
Very exciting, we're going to see some serious "at scale" behavioral changes (obesity decline, addiction decline, possibly even social media usage decline) as soon as the cost of GLP-1 agonists gets driven down and manufacturing scales up.
- lushdogg 2y agoWhat else will we see? More bowel obstructions?
- philipkglass 2y agoI wonder which will happen first: discovery of effective small-molecule drugs in this class, or improvements of peptide manufacturing to the point that cheap generics become possible. There are only 7 years left on the semaglutide patent but its manufacturing is currently so complicated that I don't expect really cheap generics after patent expiration.
- vundercind 2y agoMy understanding is that the manufacturing costs have nothing whatsoever to do with why they’re so expensive. It’s already damn near aspirin-cheap to make.
- toomuchtodo 2y agoCorrect, cost is ~$5 for a month supply, and could be made for as low as 89 cents. https://doi.org/10.1001/jamanetworkopen.2024.3474 https://doi.org/10.1001/jamanetworkopen.2024.3474 https://www.fastcompany.com/91071415/your-1000-per-month-ozempic-costs-5-to-make-says-study https://www.fastcompany.com/91071415/your-1000-per-month-oze...
- 0cf8612b2e1e 2y agoI am not familiar with the specifics of manufacturing these drugs, but peptide molecules have been synthesized for decades. What makes these special? Considering the high prices of the marketed product, I would dispute the idea that generic manufacturers will not leap at the chance to get a taste. Even if it is technically complex, they have years to perfect a recipe, get it GMP qualified, and on shelves the day patents expire.
- zdragnar 2y agoUnfortunately, the story for people who discontinue the drug is less rosey. Many regain some or all of the weight lost; it appears to be a temporary alternative to stomach surgery.
- toomuchtodo 2y agoTargeted gene therapy is the end goal, versus chronic management. We bug fix the human. Think of this as pharma print statement debugging. In the interim, the drug helps those in need of intervention. https://www.fractyl.com/fractyl-health-demonstrates-significant-improvement-in-glucose-control-and-obesity-inpreclinical-studies-of-its-rejuva-glp-1-based-pancreatic-gene-therapy-glp1-pgtxcompared-to-chronic-semaglutide-at/ https://www.fractyl.com/fractyl-health-demonstrates-signific... https://www.remain1study.com/remain-1-study/ https://www.remain1study.com/remain-1-study/
- suzzer99 2y agoDoes this happen any more often than when people lose weight by other means? I was under the impression that something like 90-95% of people who lose significant weight gain a lot of it back.
- zdragnar 2y agoOther means have fewer side effects and cost insurance companies less, meaning they cost you less. Over-priced temporary fixes should be the choice of last resort, not the first one.
- sunshowers 2y agoThe overpricing is not inherent to the manufacturing of these drugs as far as I understand, it's an artifact of the American healthcare system. You know what else is a temporary fix? Vitamin C for scurvy. Your body does not produce it endogenously. You are already a lifelong patient -- all humans are -- and it just so happens that the medication to treat it is part of your diet.
- sunshowers 2y ago